Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

SEATTLE, July 16 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated a Phase 2 trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy. The single-center trial called NeoACT (NEOadjuvant Active Cellular immunoTherapy), or P07-1, which is being conducted at UCSF Helen Diller Family Comprehensive Cancer Center, has begun enrolling approximately 40 patients. NeoACT is the first of two new Phase 2 trials of PROVENGE being initiated this year.

Each patient will receive a complete course of active treatment over a one-month period beginning six to seven weeks prior to the patient's radical prostatectomy. The course of treatment will consist of three infusions of PROVENGE-two weeks apart. Multiple safety and efficacy endpoints will be evaluated including the immune response in the prostatectomy specimens and in the peripheral blood. Following radical prostatectomy, patients will be randomized to receive either a booster of PROVENGE or no booster. Patients interested in additional information about this trial may visit http://www.clinicaltrials.gov and use the search term "NeoACT."

"I am pleased to help lead the NeoACT clinical trial, given the therapeutic potential of immunotherapy for prostate cancer," stated Lawrence Fong, M.D., principal investigator of the NeoACT trial and associate professor of medicine at UCSF Helen Diller Family Comprehensive Cancer Center. "This study will provide a unique opportunity to examine the immune response to PROVENGE in
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... The " Global Endoscopy Market by Product, ... and studies the major market drivers, restraints, and opportunities in Americas, ... Browse market data tables and in-depth TOC of   ... & Technology (2011- 2016) " ...
... 2012 Oncos Therapeutics today announced the successful ... oncolytic adenovirus suggested as a potential new treatment for many ... the safety assessment part of the study. " ... r thern Europe to start a clinical study ...
Cached Medicine Technology:MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 2MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:11/23/2014)... 23, 2014 Asher Milgrom, is ... & Wellness was recently featured on International ... president and CEO of American Medical Aesthetics & Wellness, ... received a full scholarship to attend an M.D./Ph.D program ... at the University of Chicago, where his field of ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Wright & ... behalf of Ohio and West Virginia residents who allege ... health disorders due to drinking C8 contaminated water ... Parkersburg, West Virginia. According to the C8 complaints, the ... either worked or lived in at least one of ...
(Date:11/23/2014)... Salt Lake City, Utah (PRWEB) November 23, 2014 ... in individual health insurance reimbursement for small businesses, ... the new book, The End of Employer-Provided Health ... employer-provided health insurance is the greatest financial risk ... greatest challenge facing U.S. employers, small and large, ...
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
Breaking Medicine News(10 mins):Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
... for hepatitis and more , FRIDAY, Nov. 13 (HealthDay ... an extensive database about proteins produced by genes in ... the foundation for new treatments for liver disease. , ... kind for any organ, the researchers examined 10 liver-tissue ...
... the school day, survey finds , FRIDAY, Nov. 13 ... schoolyard is where bullies go to make other kids ... another popular site. , The study, presented recently ... Philadelphia, is based on survey results from more than ...
... November 12, 2009 Shire plc (LSE: SHP, NASDAQ: ... a post hoc analysis examining emotional lability from Phase ... Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms ... IV) and Connors, Parent Rating Scale-Revised Short (CPRS-RS) in ...
... ... topical cream and first aid products designed for active lifestyles, today announced its participation ... Palo Alto, California , ... Littleton, N.H. (PRWEB) November 13, 2009 -- Tender Corp ., a leading ...
... shouldn,t take oral contraceptives just to control wheezing, expert ... with asthma may notice that their asthma symptoms get ... new study confirms that fluctuating female hormone levels appear ... help ease those changes. , In women who were ...
... America,s Health (TFAH) and the Robert Wood Johnson Foundation ... finds that 71 percent of Americans favor an increased ... one of the most popular components of health reform. ... in prevention. , In the poll, conducted by Greenberg ...
Cached Medicine News:Health News:Many Kids Feel Threatened in the Classroom 2Health News:Shire reports analysis examining emotional lability in children with ADHD taking Vyvanse 2Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 2Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 3Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 4Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 5Health News:'The Pill' May Reduce Asthma Symptoms 2Health News:'The Pill' May Reduce Asthma Symptoms 3Health News:New Poll Finds 71 Percent of Americans Favor Investing More in Disease Prevention as Central to Health Reform 2Health News:New Poll Finds 71 Percent of Americans Favor Investing More in Disease Prevention as Central to Health Reform 3Health News:New Poll Finds 71 Percent of Americans Favor Investing More in Disease Prevention as Central to Health Reform 4
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: